The main causes and current principles of prevention of cardioembolic stroke
https://doi.org/10.21518/2079-701X-2015-12-78-83
Abstract
Cardiocerebral embolism is responsible for the development of 30-40% of ischemic stroke events. [1-3] Apart from its high incidence, cardioembolic stroke (CEI) is often associated with significant residual impairment of motor, speech and coordination functions, high risk of relapse, and significantly reduces the quality of life of patients. Therefore, it is relevant to timely diagnose the cardiac causes of stroke and determine the most appropriate prevention strategy.
About the Authors
A. V. Fonyakin
Research Center of Neurology, Moscow
Russian Federation
Russian Federation
L. A. Geraskina
Research Center of Neurology, Moscow
Russian Federation
Russian Federation
References
1. Сторожаков ПИ., Гендлин ГЕ., Латышева Е.В., Ганкова Е.В. Больные с клапанными пороками сердца - лечение у терапевта до и после хирургической коррекции. Журнал сердечная недостаточность, 2002, 6: 300-305.
2. Hachet O, Guenancia C, Stamboul K et al. Frequency and predictors of stroke after acute myocardial infarction. Specific aspects of in-hospital and postdischarge events. Stroke, 2014, 45: 3514-3520.
3. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 2014, 45: 2160-2236.
4. Samsa GP, Matchar DB, Goldstein LB et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med., 2000, 160: 967-973.
5. Baker W, Cios D, Sander S et al. Meta-analysis to assess the quality of warfarin control in atri-al fibrillation patients in the United States. J Manag Care Pharm., 2009, 3: 244-252.
6. Гаврисюк Е.В., Игнатьев И.В., Сычев Д.А., Маринин В.Ф. Анализ применения непрямого антикоагулянта варфарина у пациентов с постоянной формой фибрилляции предсердий в поликлинических условиях. Клиническая фармакология и терапия, 2012, 1: 42-47.
7. Connolly S, Progue J, Hart R et al., ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomized controlled trial. Lancet, 2006, 367: 1903-1912.
8. Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for the prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet, 2009, 374: 534-542.
9. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med., 2009, 361:1139-51.
10. ROCKET AF Study Investigators. Rivaroxaban -once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J, 2010, 159 (3): 340.e1-347.e1.
11. Patel MR, Mahaffey KW, Gard J et al. Rivaroxaban vs Warfarin in nonvalvular atrial fibrillation. N Engl J Med., 2011, 365: 883-891.
12. Granger ChB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med., 2011, 365: 981-992.
13. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood, 2010, 115: 15-20.
14. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med., 2011, 364: 806-817.
15. Culerbras A, Messe SR, Chaturvedi S, Kase CS, Gronseth G. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation. Report of the guideline development subcommittee of the American academy of neurology. Neurology, 2014, 82: 716-724.
16. Agnelli G, Buller HR, Cohen A et al. Oral apixa-ban for the treatment of acute venous throm-boembolism. N Engl J Med, 2013, 369: 799-808.
17. Cucchiara BL, Kasner SE. Apixaban in atrial fibrillation: from bleeding cows to 21st century medicinal chemistry. Stroke, 2011, 42: 2376-2378.
18. Суслина З.А., Пирадов М.А. (ред.). Инсульт: диагностика, лечение, профилактика. М.: МЕДпресс-информ, 2009. -288 с.: ил.
19. Petty G.W., Brown R.D., Whisnant J.P. et al. Ischemic stroke subtypes. A population-based study of functional outcome, survival and recurrence. Stroke 2000; 31: 1062-1068.
20. Urbinelli R, Bolard P, Lemesle M et al. Stroke patterns in cardio-embolic infarction in a population-based study. Neurol Res. 2001; 23: 309-314.
21. Кузнецов А.Л., Фонякин А.В., Суслина З.А. Микроцеребральная эмболия и очаговое поражение головного мозга при кардиоэмболическом инсульте. Неврологический журнал, 2002, 3: 10-12.
22. Фонякин А.В., Гераскина Л.А., Суслина З.А. Кардиальная патология при различных патогенетических подтипах ишемического инсульта. Клиническая медицина,2002, 1: 25-28.
23. Верещагин Н.В., Суслина З.А., Гераскина Л.А., Фонякин А.В. Антигипер тензивная терапия при сосудистой патологии мозга: успехи, спорные и нерешенные вопросы. Кремлевская медицина. Клинический вестник, 2003, 2: 7 - 10.
24. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Москва 2012.
25. Mooe Th, Tienen D, Karp K, Eriksson P. Long-term follow-up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era. Heart,1996,75: 252-256.
26. Hellerstein HK, Martin JW. Incidence of thromboembolic lesions accompanying myocardial infarction. Am Heart J.,1947,33: 443-446.
27. Fukuda Y, Nakamura K. The incidence of thromboembolism and hemocoagulative background in patients with rheumatic he аrt disease. Jpn Circ J.,1984,48: 599-604.
Review
For citations:
Fonyakin AV, Geraskina LA. The main causes and current principles of prevention of cardioembolic stroke. Meditsinskiy sovet = Medical Council. 2015;(12):78-83. (In Russ.) https://doi.org/10.21518/2079-701X-2015-12-78-83
Views:
397
Email this article 